Orion Pharmaceuticals has announced plans for a €30 million expansion of its production facility in Espoo, Finland, including a new filling line for its Easyhaler dry powder inhalers. The company said that it is responding to a projected increase in demand due to the perception by healthcare providers that DPIs are more sustainable than MDIs. Orion expects the project to be complete by 2026.
According to the company’s web site, the Easyhaler line currently includes fluticasone / salmeterol Easyhaler, launched in 2018, a budesonide / formoterol combination, and formoterol, budesonide, beclomethasone, and salbutamol (albuterol) DPIs.
Orion Senior VP of Global Operations Juhani Kankaanpää commented, “The investments to production capacity are significant by Orion’s standards and are intended to ensure our ability to meet the growing demand for the products we manufacture. Nubeqa and Easyhaler are important products for Orion and will be key growth drivers for the company in the coming years.”
Read the Orion Pharmaceuticals press release.
